T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$4.45B |
| 2 |
JPMorgan Chase
JPM
|
+$2.22B |
| 3 |
Atlassian
TEAM
|
+$2.08B |
| 4 |
NVIDIA
NVDA
|
+$1.81B |
| 5 |
Apple
AAPL
|
+$1.67B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$3.24B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.08B |
| 3 |
Microsoft
MSFT
|
+$2.68B |
| 4 |
Wells Fargo
WFC
|
+$1.93B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.86B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.79% |
| 2 | Healthcare | 17.2% |
| 3 | Consumer Discretionary | 15.17% |
| 4 | Financials | 10.75% |
| 5 | Communication Services | 10.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2276
RadNet
RDNT
$5.65B
| $560K | ﹤0.01% |
25,027
+2,063
| +9% | +$50.5K |
|
2277
Microvision
MVIS
$44.7M
| $555K | ﹤0.01% |
7,926
+1,623
| +26% | +$96K |
|
|
MRSN
2278
DELISTED
Mersana Therapeutics
MRSN
| $551K | ﹤0.01% |
5,521
+943
| +21% | +$110K |
|
2279
Wabash National
WNC
$515M
| $550K | ﹤0.01% |
37,056
+996
| +3% | +$17.6K |
|
2280
Kaiser Aluminum
KALU
$2.48B
| $549K | ﹤0.01% |
5,833
-4,093
| -41% | -$395K |
|
2281
Rio Tinto
RIO
$154B
| $547K | ﹤0.01% |
6,804
| – | – |
|
2282
BancFirst
BANF
$3.6B
| $546K | ﹤0.01% |
6,558
+370
| +6% | +$28.7K |
|
2283
Customers Bancorp
CUBI
$2.56B
| $545K | ﹤0.01% |
10,455
-886
| -8% | -$54K |
|
2284
VEON
VEON
$4.78B
| $545K | ﹤0.01% |
31,928
| – | – |
|
2285
Aclaris Therapeutics
ACRS
$799M
| $544K | ﹤0.01% |
31,569
-774
| -2% | -$10.6K |
|
2286
Cimpress
CMPR
$1.95B
| $541K | ﹤0.01% |
8,509
+1,229
| +17% | +$81.8K |
|
2287
AMC Global Media
AMCX
$496M
| $540K | ﹤0.01% |
13,279
+1,834
| +16% | +$74.1K |
|
2288
Uranium Energy
UEC
$4.56B
| $540K | ﹤0.01% |
117,696
+19,643
| +20% | +$72.3K |
|
2289
Laureate Education
LAUR
$5.18B
| $538K | ﹤0.01% |
45,384
+6,287
| +16% | +$76.3K |
|
|
SILK
2290
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $538K | ﹤0.01% |
13,024
+686
| +6% | +$24.1K |
|
2291
Ethan Allen Interiors
ETD
$534M
| $537K | ﹤0.01% |
20,591
+418
| +2% | +$10.8K |
|
2292
Health Catalyst
HCAT
$133M
| $535K | ﹤0.01% |
20,483
+5,142
| +34% | +$146K |
|
2293
Pitney Bowes
PBI
$2.25B
| $535K | ﹤0.01% |
102,840
+21,300
| +26% | +$115K |
|
2294
SandRidge Energy
SD
$504M
| $535K | ﹤0.01% |
33,400
-8,900
| -21% | -$115K |
|
|
SLCA
2295
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
| $532K | ﹤0.01% |
28,536
+43
| +0.2% | +$544 |
|
|
EQRXW
2296
DELISTED
EQRx, Inc. Warrant
EQRXW
| $532K | ﹤0.01% |
656,593
| – | – |
|
2297
GrafTech
EAF
$260M
| $530K | ﹤0.01% |
5,506
+429
| +8% | +$44.6K |
|
2298
Digimarc Corp
DMRC
$110M
| $529K | ﹤0.01% |
20,069
+2,000
| +11% | +$60K |
|
2299
Fidelity MSCI Information Technology Index ETF
FTEC
$21.9B
| $529K | ﹤0.01% |
4,302
| – | – |
|
2300
Sonic Automotive
SAH
$1.97B
| $528K | ﹤0.01% |
12,414
+423
| +4% | +$20.8K |
|
Similar funds
T. Rowe Price Associates's Q1 2022 Portfolio in Review
As of Q1 2022, T. Rowe Price Associates held 3,085 positions worth $992B, down 11% from $1.11T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q1 2022 filing shows 108 new, 1,637 increased, 1,059 reduced and 107 closed positions. Its largest new stake was Nutrien: 6,143,560 shares worth $639M. The largest sale was Alphabet (Google) Class C, an estimated $3.24B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2022 buy was Nutrien: 6,143,560 shares worth $639M.
- T. Rowe Price Associates added most to Tesla in Q1 2022, an estimated $4.45B increase.
- T. Rowe Price Associates's biggest Q1 2022 reduction was Alphabet (Google) Class C, cutting an estimated $3.24B.
- T. Rowe Price Associates fully exited Xilinx Inc in Q1 2022, selling an estimated $481M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $992B portfolio in Q1 2022.
- T. Rowe Price Associates opened 108 new positions and closed 107 in Q1 2022.
- T. Rowe Price Associates's portfolio value fell 11% quarter-over-quarter to $992B.
Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.